Bristol-Myers Squibb (NYS: BMY) reported earnings on April 26. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Bristol-Myers Squibb met expectations on revenues and earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share increased.
Margins expanded across the board.
Bristol-Myers Squibb booked revenue of $5.25 billion. The 16 analysts polled by S&P Capital IQ predicted a top line of $5.27 billion on the same basis. GAAP reported sales were 4.8% higher than the prior-year quarter's $5.01 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.64. The 18 earnings estimates compiled by S&P Capital IQ averaged $0.64 per share. GAAP EPS of $0.64 for Q1 were 10% higher than the prior-year quarter's $0.58 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 75.2%, 150 basis points better than the prior-year quarter. Operating margin was 34.7%, 40 basis points better than the prior-year quarter. Net margin was 21.0%, 130 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $4.53 billion. On the bottom line, the average EPS estimate is $0.50.
Next year's average estimate for revenue is $18.01 billion. The average EPS estimate is $1.96.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,651 members out of 1,758 rating the stock outperform, and 107 members rating it underperform. Among 440 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 422 give Bristol-Myers Squibb a green thumbs-up, and 18 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is outperform, with an average price target of $33.72.
Can your retirement portfolio provide you with enough income to last? You'll need more than Bristol-Myers Squibb. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.
Add Bristol-Myers Squibb to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.